Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH

12 August 2002

journal article
Published by Wiley in European Journal of Heart Failure

Vol. 4 (4) , 559-561
https://doi.org/10.1016/s1388-9842(02)00121-6

Abstract

This article continues a series of reports on recent research developments in the field of heart failure. Reports of two key presentations made at the European Society of Cardiology Heart Failure Update meeting held in Oslo, Norway from 8 to 11 June 2002, are included in this article. Summaries of the results of the RENEWAL (RENAISSANCE and RECOVER) and ATTACH studies, presented at the Hot Line sessions held during the meeting are reported.

Keywords

This publication has 10 references indexed in Scilit:

How to assess new treatments for the management of heart failure: composite scoring systems to assess the patients’ clinical journey
European Journal of Heart Failure, 2002
Is aspirin ″the weakest link” in cardiovascular prophylaxis? The surprising lack of evidence supporting the use of aspirin for cardiovascular disease
Progress in Cardiovascular Diseases, 2002
For Debate: Preventing atherosclerotic events with aspirin
BMJ, 2002
Tumor Necrosis Factor Antagonism With Etanercept Improves Systemic Endothelial Vasoreactivity in Patients With Advanced Heart Failure
Circulation, 2001
A glossary of circulating cytokines in chronic heart failure
European Journal of Heart Failure, 2001
Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure
Journal of Cardiac Failure, 2001
Results of Targeted Anti–Tumor Necrosis Factor Therapy With Etanercept (ENBREL) in Patients With Advanced Heart Failure
Circulation, 2001
How are cytokines activated in heart failure?
European Journal of Heart Failure, 1999
The LIDO, HOPE, MOXCON and WASH studies
European Journal of Heart Failure, 1999
Safety and Efficacy of a Soluble P75 Tumor Necrosis Factor Receptor (Enbrel, Etanercept) in Patients With Advanced Heart Failure
Circulation, 1999